



COMMIT: A Community Grant Programme within LEGA-C (Local Elimination programs leading to Global Action in HCV)

Background

Gilead Sciences Inc. is a leading biopharmaceutical company that discovers, develops and commercializes innovative medicine in areas of unmet medical need. We strive to transform the promise of science and technology into therapies that have the power to cure diseases or revolutionize the standard of care. Gilead is committed to patients with liver disease and supporting efforts to achieve HCV elimination.

Programme Description

Through the Gilead EMEA Corporate Contributions Programme, Gilead intends to support the efforts of community-based organisations, public health or social care institutions, harm reduction centres or similar umbrella organisations that demonstrate the ability to deliver projects aimed at or support the elimination of hepatitis C (“HCV”) within a specific population or setting.

Selection Criteria

Gilead will consider applications that reach diverse geographic locations within Europe, the Middle East and Australia (EMEA). In particular, Gilead welcomes proposals which target specific micro elimination goals aimed at specific populations or locations, including but not limited to:

- Prisoners
- People who Use Drugs (**PWUD**) either currently or formerly, who may not be engaged with interventions such as Opioid Substitution Therapy (**OST**), Needle Exchange Programmes (**NEP**) or Treatment as Prevention (**TasP**)
- Elimination efforts focused within one city or geographic location
- People co-infected with HIV
- Generational cohorts (such as Baby Boomers)
- Resource limited settings (such as hospitals, clinics or harm reduction centres)

Projects must provide specific, measurable, achievable, realistic and time-sensitive objectives and action steps required to meet project goals, including information regarding the applicant’s capacity to implement the project and clear details on how data will be collected and analysed, and by whom. Proposals must highlight a clear communication plan following results of the project.



Eligibility

Organisations must be classified as not-for-profit and headquartered in the EMEA region with an interest in public health, including but not limited to providing health or social services, education or advocacy for underserved or hard to reach populations. Projects should intend to positively impact specific communities within the EMEA region.

Evaluation and Reporting

Grantee organisations will be required to submit interim and final project and financial reports once the project has been completed. Through the reporting process and related data collection, Gilead hopes to create opportunities to learn from both the successes and challenges faced by our partners, and to assess ways to increase the impact of future programmes.

Application Process

Organisations are required to submit their requests using the online application form, which can be accessed by clicking <https://www.gilead.com/purpose/giving/grant-funding/apply-europe>. Please review the grant Terms and Conditions prior to submitting an application. Please ensure that the 'COMMIT programme' tag is selected within the application form.

Enquiries

Questions about the announcement or application process should be submitted to EMEAgrants@gilead.com.

Key Dates and Deadlines

Application period opens: Monday 1st April 2019
Deadline to submit proposals: Friday 28th June 2019
Grant period begins: 1st September 2019
Interim report due: 1st March 2020

Grant Awards

Grant requests of up to 100,000 GBP will be considered for projects with a timeline for completion of up to, but no more than 12 months. Projects of shorter duration accompanied with a smaller budget will also be considered. Grant requests should be proportional to the scope, complexity and reach/impact of the programme, while reflecting reasonable, good faith estimates of the true operational costs related to the proposed project. Gilead will require any unused grant funds to be returned at the end of the project, in accordance with the grant Terms and Conditions and has the right to request reasonable and appropriate documentation from the grantee in relation to the grant activities. Indirect costs of 10 percent may be requested on top of direct programme costs.



Funding Restrictions

Gilead funding cannot support:

- Medications or purchasing of medications
- Existing financial deficits within an organisation
- Clinical research or clinical trials
- Projects that directly influence or advance Gilead's business, including purchase, utilisation, prescribing, formulary position, pricing, reimbursement, referral, recommendation or payment for products
- Individuals, individual healthcare providers or physician group practices
- Events or programs that have already occurred
- Government lobbying activities
- Organisations that discriminate on the basis of race, colour, gender, religion, disability, sexual orientation, or gender identity or expression.

Disclaimer Statement

- Application to the EMEA Corporate Contributions Programme is not a promise of funding
- Gilead reserves the right to approve or decline any application
- Award of a grant in any one year does not imply that a subsequent grant will be awarded without further application and approval.